Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML [Yahoo! Finance]
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression [Yahoo! Finance]
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression